Company profile for Vima Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders. We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease. Vima brings together a team of physicians, scientists, and drug developers with deep ex...
Vima Therapeutics is a clinical-stage biotechnology company pioneering a new era in the treatment of dystonia and related movement disorders. We are advancing VIM0423, a potential first-in-class oral therapy for dystonia, with the goal of helping individuals regain control of their movements by targeting the underlying cause of the disease. Vima brings together a team of physicians, scientists, and drug developers with deep expertise in movement disorders and a shared commitment to deliver a meaningful oral therapy for patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, Massachusetts
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

IPhEB Russia

Not Confirmed

envelop Contact Supplier

IPhEB Russia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/03/11/3253629/0/en/Vima-Therapeutics-Announces-First-Dystonia-Patient-Dosed-in-Phase-2-Study-and-Extension-of-Series-A-to-100-Million-to-Advance-Potential-First-in-Class-Oral-Therapy-for-Dystonia-and.html

GLOBENEWSWIRE
11 Mar 2026

https://www.globenewswire.com/news-release/2025/05/29/3090216/0/en/Vima-Therapeutics-Launches-to-Advance-the-First-Oral-Therapy-for-People-with-Dystonia-and-Related-Movement-Disorders.html

GLOBENEWSWIRE
29 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty